Место Таксотера в терапии метастатического рака молочной железы

1. Cardoso F, Bedard PhL, Winer EP et al. International Guidelines for Management of Metastatic Breast Cancer: Combination vs Sequential Single-Agent Chemotherapy. J Natl Cancer Inst 2009; 101: 1174–81.
2. Chan S, Friedrichs K, Noel D et al. Prospective randomized trial of docetaxel versus doxorubicin in patients with metastatic breast cancer. J Clin Oncol 1999; 17 (8): 2341–54.
3. Jones SE, Overmoyer B et al. Randomized phase III study of docetaxel compared with paclitaxel in metastatic breast cancer. J Clin Oncol 2005; 23 (24): 5542–51.
4. Harvey V, Mouridsen H, Semiglazov V et al. J Clin Oncol 2006; 24: 4963–70.
5. Palmeri L, Vaglica M, Palmeri S. Weekly docetaxel in the treatment of metastatic breast cancer. Ther Clin Risk Manag 2008; 4 (5): 1047–59.
6. Rivera E., Mejia JA, Arun BK et al. Phase 3 study comparing the use of docetaxel on an every-3-week versus weekly schedule in the treatment of metastatic breast cancer. Cancer 2008; 112 (7): 1455–61.
7. Valero V, Jones SE, Von Hoff DD. A phase II study of docetaxel in patients with paclitaxel-resistant metastatic breast cancer. JCO 1998, 16: 3362.
8. Krell J, Harper-Wynne C, Miles D et al. What is the evidence for rechallenging with anthracyclines or taxanes in metastatic breast cancer? A rewiew data. Proc Am Soc Clin Oncol 2009; 58s, (abstr 1070).
9. Piccart-Gebhart MJ, Burzykowski T, Buyse M et al. Taxanes Alone or in Combination With Anthracyclines As First-Line Therapy of Patients With Metastatic Breast Cancer. J Cli Oncol 2008; 26: 1980–86.
10. Стенина М.Б. Таксол (паклитаксел): механизм действия, факмакокинетика и взаимодействие с другими препаратами. В кн.: Таксол в клинической практике. Под ред. Н.И.Переводчиковой. М.: Изд-во «Полина», 2001.
11. Манзюк Л.В. Дозы и режимы введения Таксола. В кн.: Таксол в клинической практике. Под ред. Н.И.Переводчиковой. М.: Изд-во «Полина», 2001.
12. Lembersky S, Anderson R, Smith A et al. Phase II Trial of Doxorubicin and Docetaxel for Locally Advanced and Metastatic Breast Cancer: Preliminary Results from NSABP BP-57. Pr. ASCO 2000; 19: 403.
13. Raab G, Wilke H, Eidtmann H et al. Phase II Stady of Docetaxel and Epirubicin as First Line Chemotherapy in Metastatic Breast Cancer. Pr. ASCO 2000; 19: 442.
14. Malinovszky K, Johnston S, Barrett-Lee P et al. TEXAS (Taxotere Experience with Anthracyclines Study) trial: mature results of activity/toxicity of docetaxel given with anthracyclines in a community setting, as first line therapy for MBC. Cancer Chemother Pharmacol 2007; 59 (3): 413–8.
15. Nabholtz JM, Falkson C, Campos D et al. TAX 306 Study Group. Docetaxel and doxorubicin compared with doxorubicin and cyclophosphamide as first-line chemotherapy for metastatic breast cancer: results of a randomized, multicenter, phase III trial. J Clin Oncol 2003; 21 (6): 968–75.
16. Bontenbal M, Creemers GJ, Braun HJ et al. Dutch Community Setting Trial for the Clinical Trial Group. Phase II to III study comparing doxorubicin and docetaxel with fluorouracil, doxorubicin, and cyclophosphamide as first-line chemotherapy in patients with metastatic breast cancer: results of a Dutch Community Setting Trial for the Clinical Trial Group of the Comprehensive Cancer Centre. J Clin Oncol 2005; 23 (28): 7081–8.
17. Bonneterre J, Dieras V, Tubiana-Hulin M et al. Phase II multicentre randomised study of deocetaxel plus epirubicinversus 5-fluorouracil plus epirubicin and cyclophosphamide in metastatic breast cancer. Br J Cancer 2004; 91: 1466–71.
18. Mackey JR, Paterson A, Dirix L et al. Final results of the phase III randomised trial comparing docetaxel (T), doxorubicin (A) and cyclophosphamide (C) to FAC as first line chemotherapy (CT) for patients (pts) with metastatic breast cancer (MBC). Proc Am Soc Clin Oncol 2002; 21: 35a (abstr 137).
19. Goldie JH, Coldman AJ, Gudauskas GA. Rationale for the use of alternating non-cross-resistant chemotherapy. Cancer Treat Rep 1982; 66: 439–49.
20. Alba E, Mart?n M, Ramos M. Multicenter randomized trial comparing sequential with concomitant administration of doxorubicin and docetaxel as fi rst-line treatment of metastatic breast cancer: a Spanish Breast Cancer Research Group (GEICAM-9903) phase III study. J Clin Oncol 2004; 22: 2587–93.
21. Cresta S, Grasselli G, Mansutti M et al. Annals of Oncology 2004; 15: 433–9.
22. Sawada N, Ishikawa T, Fukase Y et al. Induction of thymidine phosphorylase activity and enhancement of capecitabine efficacy by Taxol/Taxotere in human cancer xenografts. Clin Cancer Res 1998; 4: 1013–21.
23. O’Shaughnessy J, Miles D, Vukelja S et al. Superior survival with capecitabine plus docetaxel combination therapy in anthracycline-pretreated patients with advanced breast cancer: phase III trial results. J Clin Oncol 2002; 20 (12): 2812–23.
24. Beslija S, Obralic N, Basic H et al. Randomized trial of sequence vs. combination of capecitabine (X) and docetaxel (T): XT vs. T followed by X after progression as fi rst-line therapy for patients (pts) with metastatic breast cancer (MBC). J Clin Oncol 2006; 24 (18S): 571.
25. Gluck, S, Russell C, O'Shaughnessy J. Relationship between survival and estrogen receptor (ER) status in pts with metastatic breast cancer (MBC(treated with capecitabine C and docetaxel (D): an exploratory data analysis. Proc Am Soc Clin Oncol 2009: 1024.
26. Lin YC, Chang HK et al. An open-labeled phase II trial of docetaxel in combination with cisplatin as first-line cytotoxic therapy for anthracycline-naive patients with metastatic breast cancer. Anticancer Drugs 2007; 18 (10): 1213–9.
27. Mavroudis D, Alexopoulos A et al. Salvage Treatment of Metastatic Breast Cancer with Docetaxel and Carboplatin. Oncology 2003; 64: 207–12.
28. Seidman AD, Brufsky A, Ansari R et al. Phase III of gemcitabine plus docetaxel (GD) compared to capecitabine plus docetaxel (CD) with planned crossover to the alternate single agent in metastatic breast cancer (MBC). Proc Am Soc Clin Oncol 2009; 41s (abstr. 1000).
29. Chan S, Romieu G, Huober J. Phase III Study of Gemcitabine Plus Docetaxel Compared With Сapecitabine Plus Docetaxel for Anthracycline-Pretreated Patients With Metastatic Breast Cancer. J Clin Oncol 2009; 27 (11): 1753–60.
30. Bachelot T, Bajard A, Ray-Coquard I et al. Superiority of Docetaxel+ Capecitabine compared to Docetaxel+Epirubicin as first-line therapy for metastatic breast cancer final results of the ERASME-4 study. Cancer Res 2009; 29 (24 Suppl.): 625s (abstr. 2099).
31. Mavroudis D, Papakotoulas P, Ardavanis A. Randomized phase III trial comparing docetaxel plus epirubicin versus docetaxel plus capecitabine as firstline treatment in women with advanced breast cancer. Annals Oncol 2010; 21: 48–54.
32. Pergam MD, Konecny GE, O’Callaghan C et al. Rational combinations of trastusumab with chemotherapeutic drugs used in the treatment of human breast cancer. J Natl Cancer Inst 2004; 96: 739–49.
33. Pergam MD, Hsu S, Lewis G et al. Inhibitory effects of combinations of HER-2/neu antibody and chemotherapeutic agents used for treatment of human breast cancers. Oncogene 1999; 18: 2241–51.
34. Marty M, Cognetti F, Maraninchi D et al. Randomized Phase II Trial of the Efficacy and Safety of Trastuzumab Combined With Docetaxel in Patients With Human Epidermal Growth Factor Receptor 2–Positive Metastatic Breast Cancer Administered As First-Line Treatment: The M77001 Study Group. J Clin Oncol 2005; 23: 4265–74.
35. Wardley A, Pivot X et al. Randomized Phase II Trial of First-Line Trastuzumab Plus Docetaxel and Capecitabine Compared With Trastuzumab Plus Docetaxel in HER2-Positive Metastatic Breast Cancer. J Clin Oncol 2010; 28: 976–83.
36. Pegram M, Forbes J, Pienkowski T et al. BCIRG 007: First overall survival analysis of randomized phase III trial of trastuzumab plus docetaxel with or without carboplatin as first line therapy in HER2 amplified metastatic breast cancer (MBC). Proc Am Soc Clin Oncol 2007; 1 (25): 18S (abstr. LBA100).
37. Miles D, Chan A, Romieu G et al. Randomized, double-blind, placebo-controlled, phase III study of bevacizumab with docetaxel or docetaxel with placebo as first-line therapy for patients AVADO. J Clin Oncol 2008; 26 (suppl): abstr LBA1011.
38. Pivot Х, Verma S, Thomssen C et al. Clinical benefit of bevacizumab (BV) plus first-line docetaxel (D) in elderly patients (pts) with locally recurrent (LR) or metastatic breast cancer (mBC): AVADO study. Proc Am Soc Clin Oncol (J Clin Oncol) 2009; 27: 15s (suppl; abstr 1094).

Е.В.Артамонова

РОНЦ им. Н.Н.Блохина, Москва